Ignite Creation Date:
2025-12-24 @ 11:10 PM
Ignite Modification Date:
2026-01-03 @ 8:38 PM
Study NCT ID:
NCT05529069
Status:
RECRUITING
Last Update Posted:
2025-10-24
First Post:
2022-09-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-01-25
Start Date Type:
ACTUAL
Primary Completion Date:
2027-04-28
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-04-28
Completion Date Type:
ESTIMATED
First Submit Date:
2022-09-01
First Submit QC Date:
None
Study First Post Date:
2022-09-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-23
Last Update Post Date:
2025-10-24
Last Update Post Date Type:
ESTIMATED